APOPTOSIS IN BONE-MARROW BIOPSY SAMPLES INVOLVING STROMAL AND HEMATOPOIETIC-CELLS IN 50 PATIENTS WITH MYELODYSPLASTIC SYNDROMES

被引:388
作者
RAZA, A
GEZER, S
MUNDLE, S
GAO, XZ
ALVI, S
BOROK, R
RIFKIN, S
IFTIKHAR, A
SHETTY, V
PARCHARIDOU, A
LOEW, J
MARCUS, B
KHAN, Z
CHANEY, C
SHOWEL, J
GREGORY, S
PREISLER, H
机构
[1] RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT PATHOL,CHICAGO,IL 60612
[2] NW COMMUNITY HOSP,ARLINGTON HTS,IL
关键词
D O I
10.1182/blood.V86.1.268.bloodjournal861268
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cell-cycle kinetics were measured in situ after infusions of iododeoxyuridine and/or bromodeoxyuridine in 50 patients with myelodysplastic syndromes (MDS) and the median labeling index in bone marrow (BM) biopsy samples was 28.6%. Unfortunately, 26 of 50 patients showed that greater than or equal to 75% of hematopoietic cells of all three lineages were undergoing programmed cell death (PCD) in their biopsy samples as shown by the in situ end labeling (ISEL) technique. Ten patients had 1/3 and eight had 2/3 ISEL(+) cells. Stromal cells were frequently ISEL(+) and often S-phase cells were also found to be simultaneously ISEL(+). Nucleosomal DNA fragments as a ladder in agarose gel were present in BM aspirates of four patients who showed high ISEL and were absent in two who had no ISEL staining in biopsy samples, but only when DNA was extracted after a 4-hour in vitro incubation in complete medium. Therefore, laddering data confirmed the ISEL findings that the majority of hematopoietic cells in MDS are in early stages of PCD. We conclude that extensive intramedullary cell death may explain the paradox of pancytopenia despite hypercellular marrows in MDS patients. Investigating approaches that protect against PCD in some MDS subsets would be of interest. (C) 1995 by The American Society of Hematology.
引用
收藏
页码:268 / 276
页数:9
相关论文
共 35 条
  • [1] CLONALITY OF CELL-POPULATIONS IN REFRACTORY-ANEMIA USING COMBINED APPROACH OF GENE LOSS AND X-LINKED RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISM METHYLATION ANALYSES
    ABRAHAMSON, G
    BOULTWOOD, J
    MADDEN, J
    KELLY, S
    OSCIER, DG
    RACK, K
    BUCKLE, VJ
    WAINSCOAT, JS
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1991, 79 (04) : 550 - 555
  • [2] ANASTASI J, 1993, BLOOD, V81, P1580
  • [3] ANDERSON JE, 1993, BLOOD, V82, P677
  • [4] PROPOSALS FOR THE CLASSIFICATION OF THE MYELODYSPLASTIC SYNDROMES
    BENNETT, JM
    CATOVSKY, D
    DANIEL, MT
    FLANDRIN, G
    GALTON, DAG
    GRALNICK, HR
    SULTAN, C
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (02) : 189 - 199
  • [5] APOPTOSIS IS A COMMON HISTOPATHOLOGICAL FINDING IN MYELODYSPLASIA - THE CORRELATE OF INEFFECTIVE HEMATOPOIESIS
    CLARK, DM
    LAMPERT, IA
    [J]. LEUKEMIA & LYMPHOMA, 1990, 2 (06) : 415 - 418
  • [6] DEZUBE BJ, 1993, J ACQ IMMUN DEF SYND, V6, P787
  • [7] THE ORIGINS OF DNA BREAKS - A CONSEQUENCE OF DNA DAMAGE, DNA-REPAIR, OR APOPTOSIS
    EASTMAN, A
    BARRY, MA
    [J]. CANCER INVESTIGATION, 1992, 10 (03) : 229 - 240
  • [8] FEHSEL K, 1991, AM J PATHOL, V139, P251
  • [9] TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH HEMATOPOIETIC GROWTH-FACTORS
    GANSER, A
    HOELZER, D
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1992, 6 (03) : 633 - 653
  • [10] GIAVRIELI Y, 1992, J CELL BIOL, V119, P493